372 related articles for article (PubMed ID: 31743738)
1. Geroprotection in the future. In memoriam of Joseph Knoll: The selegiline story continues.
Ferdinandy P; Yoneda F; Muraoka S; Fürst S; Gyires K; Miklya I
Eur J Pharmacol; 2020 Feb; 868():172793. PubMed ID: 31743738
[TBL] [Abstract][Full Text] [Related]
2. A longevity study with enhancer substances (selegiline, BPAP) detected an unknown tumor-manifestation-suppressing regulation in rat brain.
Knoll J; Baghy K; Eckhardt S; Ferdinandy P; Garami M; Harsing LG; Hauser P; Mervai Z; Pocza T; Schaff Z; Schuler D; Miklya I
Life Sci; 2017 Aug; 182():57-64. PubMed ID: 28623006
[TBL] [Abstract][Full Text] [Related]
3. The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).
Miklya I
Mol Psychiatry; 2016 Nov; 21(11):1499-1503. PubMed ID: 27480491
[TBL] [Abstract][Full Text] [Related]
4. Longevity study with low doses of selegiline/(-)-deprenyl and (2R)-1-(1-benzofuran-2-yl)-N-propylpentane-2-amine (BPAP).
Knoll J; Miklya I
Life Sci; 2016 Dec; 167():32-38. PubMed ID: 27777099
[TBL] [Abstract][Full Text] [Related]
5. [Slowing the age-induced decline of brain function with prophylactic use of (-)-deprenyl (Selegiline, Jumex). Current international view and conclusions 25 years after the Knoll's proposal].
Miklya I
Neuropsychopharmacol Hung; 2009 Dec; 11(4):217-25. PubMed ID: 20150659
[TBL] [Abstract][Full Text] [Related]
6. [History of deprenyl--the first selective inhibitor of monoamine oxidase type B].
Knoll J
Vopr Med Khim; 1997; 43(6):482-93. PubMed ID: 9503565
[TBL] [Abstract][Full Text] [Related]
7. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain.
Knoll J
Pharmacol Toxicol; 1998 Feb; 82(2):57-66. PubMed ID: 9498233
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic actions of L-deprenyl in dogs: a model of human brain aging.
Ruehl WW; Neilson J; Hart B; Head E; Bruyette DS; Cummings BJ
Adv Pharmacol; 1998; 42():316-9. PubMed ID: 9327904
[No Abstract] [Full Text] [Related]
9. Deprenyl (selegiline): the history of its development and pharmacological action.
Knoll J
Acta Neurol Scand Suppl; 1983; 95():57-80. PubMed ID: 6428148
[TBL] [Abstract][Full Text] [Related]
10. Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders.
Berry MD; Juorio AV; Paterson IA
Prog Neurobiol; 1994 Oct; 44(2):141-61. PubMed ID: 7831475
[No Abstract] [Full Text] [Related]
11. MAO-B inhibitors for the treatment of Parkinson's disease.
Mov Disord; 2002; 17 Suppl 4():S38-44. PubMed ID: 12211138
[No Abstract] [Full Text] [Related]
12. [A comparison of the pharmacology of (-)-deprenyl to N-methylpropargylamine-1-aminoindane (J-508) and rasagiline, the desmethyl-analogue of J-508].
Miklya I
Neuropsychopharmacol Hung; 2008 Mar; 10(1):15-22. PubMed ID: 18771016
[TBL] [Abstract][Full Text] [Related]
13. Selegiline reduces cisplatin-induced neuronal death in neuroblastoma cells.
Müller T; Przuntek H; Rieks M; Mackowiak A
Neurol Res; 2008 May; 30(4):417-9. PubMed ID: 18237459
[TBL] [Abstract][Full Text] [Related]
14. Neuroprotection by selegiline and other MAO inhibitors.
Stern G
J Neural Transm Suppl; 1998; 52():99-107. PubMed ID: 9564613
[TBL] [Abstract][Full Text] [Related]
15. A pharmacological analysis elucidating why, in contrast to (-)-deprenyl (selegiline), alpha-tocopherol was ineffective in the DATATOP study.
Miklya I; Knoll B; Knoll J
Life Sci; 2003 Apr; 72(23):2641-8. PubMed ID: 12672509
[TBL] [Abstract][Full Text] [Related]
16. Selegiline's neuroprotective capacity revisited.
Riederer P; Lachenmayer L
J Neural Transm (Vienna); 2003 Nov; 110(11):1273-8. PubMed ID: 14628191
[No Abstract] [Full Text] [Related]
17. MAO inhibitors.
Keller D
Cleve Clin J Med; 2011 Feb; 78(2):81; author reply 81. PubMed ID: 21365960
[No Abstract] [Full Text] [Related]
18. The Monoamine Oxidase-B Inhibitor Selegiline Does Not Affect
Li XY; Jiao FY; Yao RX; Ju ZZ; Chen MJ; Ge JJ; Li G; Sun YM; Wu P; Wu JJ; Yen TC; Zuo C; Wang J; Lu JY; Liu FT;
Mov Disord; 2023 Apr; 38(4):705-707. PubMed ID: 36707403
[No Abstract] [Full Text] [Related]
19. Do antioxidant strategies work against aging and age-associated disorders? Propargylamines: a possible antioxidant strategy.
Kitani K; Minami C; Yamamoto T; Maruyama W; Kanai S; Ivy GO; Carrillo MC
Ann N Y Acad Sci; 2001 Apr; 928():248-60. PubMed ID: 11795516
[TBL] [Abstract][Full Text] [Related]
20. The facilitation of dopaminergic activity in the aged brain by (-)deprenyl. A proposal for a strategy to improve the quality of life in senescence.
Knoll J
Mech Ageing Dev; 1985 May; 30(2):109-22. PubMed ID: 3927074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
